ProShares Ultra NASDAQ Biotechnology
23 hedge funds and large institutions have $4.04M invested in ProShares Ultra NASDAQ Biotechnology in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
102% more call options, than puts
Call options by funds: $332K | Put options by funds: $164K
12% more capital invested
Capital invested by funds: $3.62M → $4.04M (+$425K)
1.59% more ownership
Funds ownership: 5.91% → 7.5% (+1.6%)
4% less funds holding
Funds holding: 24 → 23 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$1.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$267K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$87.8K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$53.6K |
| 5 |
GC
Garde Capital
Seattle,
Washington
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCWM
Cassaday & Co Wealth Management
Mclean,
Virginia
|
-$228K |
| 2 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
-$203K |
| 3 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$162K |
| 4 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$162K |
| 5 |
CWM
Crowley Wealth Management
Wilmington,
Delaware
|
-$50.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CWM
26
Crowley Wealth Management
Wilmington,
Delaware
| – | -$50.7K | -1,000 | Closed |
|
27
US Bancorp
Minneapolis,
Minnesota
| – | -$25.3K | -500 | Closed |
|
|
BOJHT
28
Bank of Jackson Hole Trust
Jackson,
Wyoming
| – | -$7.6K | -150 | Closed |
|
29
Simplex Trading
Chicago,
Illinois
| – | -$3K | -67 | Closed |
|
BIB Hedge Fund Activity: Q1 2025 in Review
23 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2025, worth a combined $4.04M — up 12% from $3.62M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIB and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 2 added.
The largest buyer was IMC Chicago, opening a new position worth an estimated $1.2M. The largest seller was Cassaday & Co Wealth Management, exiting entirely with an estimated $228K sold.
- 23 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2025, down from 24 in Q4 2024.
- Funds reported $4.04M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2025, up 12% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2025 and 6 closed out, a net change of -1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2025 was IMC Chicago, an estimated $1.2M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2025 was Cassaday & Co Wealth Management, an estimated $228K sold.
Based on aggregated 13F filings for Q1 2025.